2020
Prescribed medical cannabis in women with gynecologic malignancies: A single-institution survey-based study
Webster EM, Yadav GS, Gysler S, McNamara B, Black J, Tymon-Rosario J, Zeybek B, Han C, Arkfeld CK, Andikyan V, Menderes G, Huang G, Azodi M, Silasi DA, Santin AD, Schwartz PE, Ratner ES, Altwerger G. Prescribed medical cannabis in women with gynecologic malignancies: A single-institution survey-based study. Gynecologic Oncology Reports 2020, 34: 100667. PMID: 33204797, PMCID: PMC7653050, DOI: 10.1016/j.gore.2020.100667.Peer-Reviewed Original ResearchTreatment-related symptomsGynecologic malignanciesMedical cannabisOpioid usePatient experienceBetter side effect profileDecrease opioid useGynecologic oncology populationPercent of patientsSide effect profileSubset of patientsBone painEligible patientsAbdominal painNeuropathic painRecurrent diseaseSymptom controlJoint painAdjunct therapyOncology populationEffect profileGynecologic oncologistsTraditional medicationsPainPatients
2011
Urinary hCG Screening in the Gynecologic Oncology Population
Richter C, Buza N, Hui P, Silasi D, Azodi M, Santin A, Rutherford T, Schwartz P. Urinary hCG Screening in the Gynecologic Oncology Population. Journal Of Gynecologic Surgery 2011, 27: 143-146. DOI: 10.1089/gyn.2010.0048.Peer-Reviewed Original ResearchGestational trophoblastic diseasePositive urine pregnancy testUrine pregnancy testGynecologic malignanciesUrinary hCGTrophoblastic diseasePregnancy testHuman chorionic gonadotropin testingClear cell ovarian carcinomaGynecologic oncology clinicGynecologic oncology populationRetrospective chart reviewHCG testingChart reviewNonpregnant patientsConsecutive patientsOncology populationPrimary peritonealOncology clinicVaginal carcinomaNongynecologic malignanciesUterine cancerFallopian tubeOvarian carcinomaOvarian cancer